register

News & Trends - Biotechnology

Brisbane-based Microba partners with UNSW Sydney’s Microbiome Research Centre to deliver world-class analysis

Health Industry Hub | September 25, 2019 |

Australia’s gut microbiome testing specialists Microba have partnered with the Microbiome Research Centre (MRC) at UNSW to power new gut microbiome research to discover new links with disease states and potential therapeutics.

The collaboration between Microba and the MRC combines world-class microbiome analysis with leading clinicians and scientists, sharing a vision to not only discover new links with disease states, but with the ultimate goal of developing new diagnostics and therapies to help patients.

MRC held its official opening 12 August and will investigate how disturbance in the microbiome occurs and how it causes disease – a critical step in preventing it.

Microba co-founder and microbiome research pioneer, Professor Phil Hugenholtz welcomed the partnership, explaining that this opportunity would enable some of Australia’s best researchers to access the best analytical tools available.

“We hope that by furthering our knowledge of the gut microbiome, we will be able to improve the health and wellbeing of individuals. This collaboration allows all parties involved to contribute to this vision,” he said.

“With at least half of the population complaining of a digestive issue each year, high-powered research is essential to provide diagnostics and therapeutics into the future.”

Showcase your expertise and the value your business delivers, share industry-specific news, solutions, job ads and more with our subscribers. Contact us

The MRC is directed by UNSW Medicine Professor Emad El-Omar, a well recognised clinical gastroenterologist specialist with 20 years of gut microbiome research experience.  Professor El-Omar is also the Editor in Chief of the highly reputable journal, Gut.

“We are delighted to collaborate with Microba, a company underpinned by outstanding scientists at the cutting edge of research in the microbiome field,” he said.

“Our complementary strengths will deliver real benefits to patients the world over.

“The microbiome is an exciting new frontier in medicine and together we will harness its power to treat and prevent disease.”

You may also like Australian Biotech 2030 Vision to emerge from AusBiotech CEO Policy Forum


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.